The inhibitory GABA system as a therapeutic target for cognitive symptoms in schizophrenia: investigational agents in the pipeline
The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
IMPORTANCE OF THE FIELD: Cognitive impairments associated with schizophrenia include neuropsychological deficits in attention, working memory, learning and executive function. Because these cognitive deficits precede the onset of psychosis, are present in non-affected relatives and constitute the best predictor of functional outcome, they are a cardinal clinical feature in schizophrenia. Currently, no effective treatment for the cognitive symptoms in schizophrenia exists. AREAS COVERED IN THIS REVIEW: There is evidence that the inhibitory GABA system is affected in schizophrenia, suggesting that cognitive impairments associated with schizophrenia may be effectively treated by drugs that modulate the GABA(A) receptor. However, classical benzodiazepines produce cognitive impairments and are associated with numerous side effects. The recent development of compounds with selective efficacy for different α subunits at the benzodiazepine site of the GABA(A) receptor has renewed interest for the therapeutic potential of GABAergic drugs. WHAT THE READER WILL GAIN: This review summarizes the involvement of the inhibitory GABA system in the cognitive abnormalities of schizophrenia and discusses putative (selective) GABAergic cognition-enhancing drugs for schizophrenia. TAKE HOME MESSAGE: If cognitive abnormalities in schizophrenic individuals are the result of GABAergic dysfunction, selectively modulating the GABA system could comprise a promising therapeutic intervention for cognitive symptoms in schizophrenia.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Dopamine Hypothesis of Schizophrenia: Version III--The Final Common Pathway
Howes, O. D., & Kapur, S. (2009) · Schizophrenia Bulletin · doi:10.1093/schbul/sbp006 · Cited by 2,693 · cited 1×
“There is strong evidence for the involvement of the dopamine and glutamate receptor systems in the pathophysiology of schizophrenia [100,101].”
BackgroundThe MATRICS Consensus Cognitive Battery, part 1: test selection, reliability, and validity
Nuechterlein, K. H., Green, M. F., Kern, R. S., Baade, L. E., Barch, D. M., Cohen, J. D., Essock, S., Fenton, W. S., Frese, F. J., Gold, J. M., et al. (2008) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2007.07010042 · Cited by 2,342
Abnormal neural oscillations and synchrony in schizophrenia
Uhlhaas, P. J., & Singer, W. (2010) · Nature Reviews Neuroscience · doi:10.1038/nrn2774 · Cited by 2,120
Neuronal Diversity and Temporal Dynamics: The Unity of Hippocampal Circuit Operations
Klausberger, T., & Somogyi, P. (2008) · Science · doi:10.1126/science.1149381 · Cited by 2,050
Synchronization of neuronal activity in hippocampus by individual GABAergic interneurons
Cobb, S. R., Buhl, E. H., Halasy, K., Paulsen, O., & Somogyi, P. (1995) · Nature · doi:10.1038/378075a0 · Cited by 1,498
Longitudinal studies of cognition and functional outcome in schizophrenia: implications for MATRICS
Green, M. F., Kern, R. S., & Heaton, R. K. (2004) · Schizophrenia Research · doi:10.1016/j.schres.2004.09.009 · Cited by 1,422 · cited 1×
“The fact that cognitive deficits precede the onset of psychosis [3], are also found in non-affected relatives of schizophrenia patients [4] and are the best predictor of functional outcome [5] suggests that cognitive impairments can be regarded as a core clinical feature in patients with schizophrenia.”
BackgroundWhich GABAA-receptor subtypes really occur in the brain?
McKernan, R. M., & Whiting, P. J. (1996) · Trends in Neurosciences · doi:10.1016/s0166-2236(96)80023-3 · Cited by 1,222
Benzodiazepine actions mediated by specific γ-aminobutyric acidA receptor subtypes
Rudolph, U., Crestani, F., Benke, D., Brünig, I., Benson, J. A., Fritschy, J.-M., Martin, J. R., Bluethmann, H., & Möhler, H. (1999) · Nature · doi:10.1038/44579 · Cited by 1,172
GABAergic Interneurons Implications for Understanding Schizophrenia and Bipolar Disorder
Benes, F. (2001) · Neuropsychopharmacology · doi:10.1016/s0893-133x(01)00225-1 · Cited by 1,082 · cited 2×
“There is ample evidence that various GABAergic deficits are present in schizophrenic patients [8,9].”
BackgroundMcKernan, R. M., Rosahl, T. W., Reynolds, D. S., Sur, C., Wafford, K. A., Atack, J. R., Farrar, S., Myers, J., Cook, G., Ferris, P., et al. (2000) · Nature Neuroscience · doi:10.1038/75761 · Cited by 944
Cannon, M., Caspi, A., Moffitt, T. E., Harrington, H., Taylor, A., Murray, R. M., & Poulton, R. (2002) · Archives of General Psychiatry · doi:10.1001/archpsyc.59.5.449 · Cited by 783
A new benzodiazepine pharmacology
Möhler, H., Fritschy, J. M., & Rudolph, U. (2002) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.300.1.2 · Cited by 716 · cited 2×
“a3 or a5 subunit, and their use is associated with a plethora of side effects including sedation, amnesia, cognitive impairment, ataxia, tolerance and the risk of withdrawal [18].”
BackgroundCognitive Effects of Long-Term Benzodiazepine Use: A Meta-Analysis
Barker, M. J., Greenwood, K. M., Jackson, M., & Crowe, S. F. (2004) · CNS Drugs · doi:10.2165/00023210-200418010-00004 · Cited by 552
GABA-based therapeutic approaches: GABAA receptor subtype functions
RUDOLPH, U., & MOHLER, H. (2006) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2005.10.003 · Cited by 499 · cited 5×
“Thus, a molecular heterogeneity depending on subunit composition ultimately determines physiological and pharmacological receptor properties and contributes to flexibility in signal transduction and modulation [14].”
BackgroundInfluentialRegulation of the GABA cell phenotype in hippocampus of schizophrenics and bipolars
Benes, F. M., Lim, B., Matzilevich, D., Walsh, J. P., Subburaju, S., & Minns, M. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0703806104 · Cited by 483 · cited 1×
“parvalbumin-positive interneurons have been demonstrated in bipolar disorder in which cognitive deficits are not as prominent as in schizophrenia [28].”
BackgroundExtrasynaptic GABA A Receptors: Form, Pharmacology, and Function
Belelli, D., Harrison, N. L., Maguire, J., Macdonald, R. L., Walker, M. C., & Cope, D. W. (2009) · The Journal of Neuroscience · doi:10.1523/jneurosci.3340-09.2009 · Cited by 464 · cited 2×
“In contrast to the direct effects of intrasynaptic GABAA receptors, tonically activated extrasynaptic GABAA receptors can modulate the excitability of neural networks without affecting neuronal sensitivity [16].”
BackgroundRao, S. G., Williams, G. V., & Goldman-Rakic, P. S. (2000) · The Journal of Neuroscience · doi:10.1523/jneurosci.20-01-00485.2000 · Cited by 407
Cognitive Dysfunction in Schizophrenia: Convergence of γ-Aminobutyric Acid and Glutamate Alterations
Lewis, D. A., & Moghaddam, B. (2006) · Archives of Neurology · doi:10.1001/archneur.63.10.1372 · Cited by 404 · cited 2×
“There is ample evidence that various GABAergic deficits are present in schizophrenic patients [8,9].”
BackgroundMechanism for top-down control of working memory capacity
Edin, F., Klingberg, T., Johansson, P., McNab, F., Tegnér, J., & Compte, A. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0901894106 · Cited by 365
Hulshoff Pol, H. E., & Kahn, R. S. (2007) · Schizophrenia Bulletin · doi:10.1093/schbul/sbm168 · Cited by 364
Self-citationHaenschel, C., Bittner, R. A., Waltz, J., Haertling, F., Wibral, M., Singer, W., Linden, D. E. J., & Rodriguez, E. (2009) · The Journal of Neuroscience · doi:10.1523/jneurosci.1428-09.2009 · Cited by 303 · cited 1×
“Generally, impaired inhibitory regulation in schizophrenia could lead to reduced neural synchronicity required for higher order information processing which could then explain cognitive impairments including deficits in working memory [92].”
BackgroundGABAergic dysfunction in schizophrenia: new treatment strategies on the horizon
Guidotti, A., Auta, J., Davis, J. M., Dong, E., Grayson, D. R., Veldic, M., Zhang, X., & Costa, E. (2005) · Psychopharmacology · doi:10.1007/s00213-005-2212-8 · Cited by 262 · cited 1×
“An example is imidazenil, which possesses a partial agonistic profile with efficacy at all benzodiazepine-sensitive a subunits, but which has been reported to possess a distinct, selective and non-sedating profile in vivo [26].”
BackgroundDias, R., Sheppard, W. F. A., Fradley, R. L., Garrett, E. M., Stanley, J. L., Tye, S. J., Goodacre, S., Lincoln, R. J., Cook, S. M., Conley, R., et al. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.1166-05.2005 · Cited by 247 · cited 1×
“a2/3 TP003 a1 (0%), a2 (< 15%), a3 (83%), a5 (< 15%) Equivalent affinity [110] a2/3 TPA123 a1 (23%), a2 (35%), a3 (43%), a5 (19%) Reinforcing efficacy and physiological dependence remained present [23]”
Yee, B. K., Keist, R., von Boehmer, L., Studer, R., Benke, D., Hagenbuch, N., Dong, Y., Malenka, R. C., Fritschy, J.-M., Bluethmann, H., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0508752102 · Cited by 201
Hashimoto, T., Nguyen, Q. L., Rotaru, D., Keenan, T., Arion, D., Beneyto, M., Gonzalez-Burgos, G., & Lewis, D. A. (2009) · Biological Psychiatry · doi:10.1016/j.biopsych.2009.01.004 · Cited by 151
Menzies, L., Ooi, C., Kamath, S., Suckling, J., McKenna, P., Fletcher, P., Bullmore, E., & Stephenson, C. (2007) · Archives of General Psychiatry · doi:10.1001/archpsyc.64.2.156 · Cited by 120
GABA transporters as drug targets for modulation of GABAergic activity
Schousboe, A., Sarup, A., Larsson, O. M., & White, H. S. (2004) · Biochemical Pharmacology · doi:10.1016/j.bcp.2004.06.041 · Cited by 96 · cited 1×
“So far, four GAT subtypes have been identified, with the highly expressed GAT-1 and GAT-4 being the most widely distributed [11].”
BackgroundMaldonado-Avilés, J. G., Curley, A. A., Hashimoto, T., Morrow, A. L., Ramsey, A. J., O’Donnell, P., Volk, D. W., & Lewis, D. A. (2009) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2008.08101484 · Cited by 91
Ator, N. A., Atack, J. R., Hargreaves, R. J., Burns, H. D., & Dawson, G. R. (2010) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.109.158303 · Cited by 66
Griebel, G., Perrault, G., Simiand, J., Cohen, C., Granger, P., Decobert, M., Françon, D., Avenet, P., Depoortere, H., Tan, S., et al. (2001) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)29437-4 · Cited by 59
Reversal of Ketamine-Induced Working Memory Impairments by the GABAAα2/3 Agonist TPA023
Castner, S. A., Arriza, J. L., Roberts, J. C., Mrzljak, L., Christian, E. P., & Williams, G. V. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2010.01.001 · Cited by 37 · cited 1×
“7 -- 5 mg/kg) acutely blocked the cognitionimpairing effects of the NMDA receptor antagonist ketamine in primates while it did not affect concomitant hallucinatorylike behaviors [77].”
Background
Cited by
Millan, M. J., Agid, Y., Brüne, M., Bullmore, E. T., Carter, C. S., Clayton, N. S., Connor, R., Davis, S., Deakin, B., DeRubeis, R. J., et al. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3628 · Cited by 1,292
Beyond classical benzodiazepines: novel therapeutic potential of GABAA receptor subtypes
Rudolph, U., & Knoflach, F. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3502 · Cited by 733
Schür, R. R., Draisma, L. W. R., Wijnen, J. P., Boks, M. P., Koevoets, M. G. J. C., Joëls, M., Klomp, D. W., Kahn, R. S., & Vinkers, C. H. (2016) · Human Brain Mapping · doi:10.1002/hbm.23244 · Cited by 349
Self-citationAls, T. D., Kurki, M. I., Grove, J., Voloudakis, G., Therrien, K., Tasanko, E., Nielsen, T. T., Naamanka, J., Veerapen, K., Levey, D. F., et al. (2023) · Nature Medicine · doi:10.1038/s41591-023-02352-1 · Cited by 324
The neurobiology and treatment of first-episode schizophrenia
Kahn, R. S., & Sommer, I. E. (2015) · Molecular Psychiatry · doi:10.1038/mp.2014.66 · Cited by 219
Self-citation
Metadata
- Authors
- Vinkers, C. H., Mirza, N. R., Olivier, B., & Kahn, R. S.
- Venue
- Expert Opinion on Investigational Drugs
- Publisher
- Informa UK Limited
- Published
- 2010-09-03
- Volume
- 19
- Issue
- 10
- Pages
- 1217-1233
- ISSN
- 1354-3784 (ISSN-L)
- 1744-7658
- OpenAlex
- W2167878578
- Cited by
- 39
- References
- 31
- FWCI
- 2.79
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.